Life Sciences IPO Scene Buzzing So Far in October

生命科学首次公开募股10月迄今风起云涌

2021-10-14 03:00:11 BioSpace

本文共1133个字,阅读需3分钟

It’s only the second week of October, and the biopharma initial public offering (IPO) scene has already been buzzing this month. Here’s a look at some of the IPO activity so far this month from companies who either filed for their IPO or began trading on the Nasdaq. Pyxis Oncology Last week, Massachusetts-based Pyxis Oncology announced the pricing of its IPO and began trading on the Nasdaq under the ticker symbol “PYXS.” Proceeds from the IPO were expected to be $168 million, with 10,500,000 shares of common stock being offered at a price of $16 per share. The offering is expected to close on October 13. Pyxis launched in 2019 and is a preclinical oncology company developing next-generation therapeutics for difficult-to-treat cancers. Entrada Therapeutics Biotechnology company Entrada Therapeutics filed for an IPO worth up to $100 million with the U.S. Securities and Exchange Commission (SEC) on Friday. Entrada plans to trade on the Nasdaq under the ticker symbol “TRDA.” Founded in 2016, the Boston-based company is working to develop Endosomal Escape Vehicle (EEV) therapeutics as a new class of medicines. In March, Entrada completed a $116 million Series B financing round. The company plans to use the funds to advance to the clinic. Cognition Therapeutics Cognition Therapeutics also finished last week with some exciting news. On Friday, the New York-based company began trading on the Nasdaq under the ticker symbol “CGTX.” The IPO offers 3,768,116 shares of common stock priced at $12 per share. Cognition is a biopharmaceutical company developing small molecule therapeutics to target age-related degenerative diseases and disorders of the nervous system. The company’s lead product candidate is currently being evaluated in a Phase II Alzheimer’s disease study. Evotec Last week, Germany-based Evotec SE filed with the SEC to raise up to $100 million in its IPO. The company is currently listed on the Frankfurt Stock Exchange. Evotec is a drug discovery and development partner for the biopharmaceutical industry. The same day as its IPO filing, the company announced that it was expanding its collaboration with Bristol Myers Squibb to include a new cell type. The goal of the partnership, which was forged in 2016 and has been expanded many times since then, is to identify disease-modifying treatments for neurodegenerative diseases. Vaxxinity Last Friday, biotechnology company Vaxxinity filed for a $100 million IPO. The Dallas-based company is pioneering a new class of medicines to democratize health. Vaxxinity was formed in April when COVAXX and United Neuroscience consolidated their vaccine development efforts. The company’s lead candidate is UB-612, a vaccine to fight SARS-CoV-2. Aura Biosciences Massachusetts-based Aura Biosciences also filed for a $100 million IPO with the SEC last week. Aura is a clinical-stage oncology company developing a novel technology platform based on the discoveries of NIH Distinguished Investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute. The company’s lead candidate is currently in Phase II development as a first-line treatment for choroidal melanoma.
现在才十月的第二周,生物制药的首次公开募股(IPO)已经在这个月热闹非凡。以下是本月到目前为止的一些IPO活动,这些企业要么提交了IPO申请,要么开始在纳斯达克交易。 Pyxis肿瘤学 上周,总部位于马萨诸塞州的Pyxis Oncology宣布了其IPO的定价,并开始在纳斯达克交易,股票代码为“Pyxs”IPO的收益预计为1.68亿美元,其中10,500,000股普通股将以每股16美元的价格发行。此次发行预计将于10月13日结束。 Pyxis于2019年推出,是一家临床前肿瘤公司,为难以治疗的癌症开发下一代疗法。 Entrada疗法 生物技术公司Entrada Therapeutics周五向美国证券交易委员会(SEC)申请了价值高达1亿美元的首次公开募股。Entrada计划在纳斯达克交易,股票代码为“TRDA” 这家总部位于波士顿的公司成立于2016年,正致力于开发内源性逃逸载体(EEV)疗法,作为一种新的药物类别。今年3月,Entrada完成了1.16亿美元的B轮融资。公司计划用这笔资金垫付到诊所。 认知治疗学 认知治疗学上周也结束了一些令人兴奋的消息。周五,这家总部位于纽约的公司开始在纳斯达克交易,股票代码为“CGTX”。此次IPO发行3,768,116股普通股,每股12美元。 Cognition是一家生物制药公司,开发小分子疗法,以针对与年龄相关的退行性疾病和神经系统疾病。该公司的主要候选产品目前正在阿尔茨海默病二期研究中进行评估。 埃沃泰克 上周,总部位于德国的Evotec SE向美国证交会提交了IPO融资高达1亿美元的申请。该公司目前在法兰克福证券交易所上市。Evotec是生物制药行业的药物发现和开发合作伙伴。 在提交IPO申请的同一天,该公司宣布将扩大与百时美施贵宝的合作,包括一种新的细胞类型。该伙伴关系成立于2016年,此后多次扩大,其目标是识别神经退行性疾病的疾病修饰疗法。 Vaxxinity 上周五,生物技术公司Vaxxinity申请了1亿美元的IPO。这家总部位于达拉斯的公司正在开创一种新的药物类别,以使健康民主化。 Vaxxinity成立于4月份,当时COVAXX和联合神经科学巩固了他们的疫苗开发努力。该公司的主要候选人是UB-612,一种对抗新型冠状病毒的疫苗。 灵光生物科学 总部位于马萨诸塞州的Aura Biosciences上周也向SEC提交了1亿美元的IPO申请。Aura是一家临床阶段肿瘤学公司,基于国家癌症研究所癌症研究中心的NIH杰出研究员John Schiller博士的发现开发了一个新的技术平台。该公司的主要候选药物目前正处于II期开发中,作为脉络膜黑色素瘤的一线治疗药物。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文